US EditionSemaglutide and Tirzepatide off FDA shortage list: What does this mean for weight loss drug access?
- The FDA approved Wegovy and Zepbound for weight loss, leading to increased discussion about GLP-1 drugs like semaglutide and tirzepatide, originally developed for diabetes management, and now widely debated in medicine and culture.
- Fueled by social media, off-label use of GLP-1 drugs has surged, with a Storyful Intelligence analysis of 29.9k mentions between February 1, 2024, and March 24, 2025, revealing discussions around conditions like PCOS and addiction.
- Some celebrities like Sharon Osbourne, who shed 42 pounds, and Whoopi Goldberg have openly discussed using weight loss injections like Ozempic and Mounjaro, while others like Gemma Collins claim these drugs have transformed their lives.
- Common side effects of GLP-1 drugs include nausea, especially when starting the medication, and more serious risks such as pancreatitis, while long-term effects remain unknown, and the new term 'Ozempic neck' refers to skin changes after using fat jabs.
- A clinical trial, STRIDE, showed that semaglutide, marketed as Ozempic and Wegovy, improved walking distance and quality of life for diabetes patients with peripheral artery disease, independent of weight loss, leading to calls for Health Canada and global guidelines to incorporate it into practice.
47 Articles
47 Articles
Hims Is Begging Customers to Lobby the FDA to Keep Its Ozempic Knockoffs Legal
You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized men's health app also offers hair loss treatment, STD meds, mental health services and GLP-1 weight loss treatments — though that's now going away. Fueled by global demand and slow production, 2024 was the year of the GLP-1 shortage. Originally used to t…
Dr. McCullough Weighs In: The History & Future of GLP-1s * 100PercentFedUp.com * by Noah
In a recent article by Dr. Peter McCullough, he explores the evolution of GLP-1 receptor agonists and their expanding role beyond diabetes treatment. The journey began in 2005 with the FDA approval of exenatide (Byetta), setting the stage for a new class of medications that regulate blood sugar and appetite. A Timeline of GLP-1 Advancements: 2005 – Exenatide (Byetta) approved for type 2 diabetes 2010 – Liraglutide (Victoza) enters the market 201…
MedPage Today
Anti-Aging, Acupuncture and Health NewsSTRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
(MedPage Today) -- CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based on two major...
The Gateway Pundit
DailyTruthReportDr. McCullough Weighs In: The History & Future of GLP-1s
Dr. Peter McCullough examines the transformative journey of GLP-1 receptor agonists, highlighting the promising future of retatrutide. This post delves into innovative treatment options that could redefine weight management.
Food vlogger Rocky Singh sheds 34 kg in a year, shuts down ‘use of Ozempic’ speculation with candid response
Rocky Singh also referenced a T-shirt from last year to highlight the difference in his weight and also addressed the ‘use of Ozempic’ speculation for his transformation
Coverage Details
Bias Distribution
- 53% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
